DPII Discovery Partners

CAMBRIDGE, Mass., Sept. 11 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. will hold a conference call to discuss the outcome of the proxy vote on the proposed reverse merger between Infinity and Discovery Partners International, Inc. (NASDAQ:DPII) scheduled for September 12, 2006. The conference call, which will be moderated by Steven Holtzman, CEO of Infinity, will also provide a business overview of the company and a discussion of its lead oncology programs. The call will be held at 8:30 a.m. EDT (5:30 a.m. PDT) on Thursday, September 14, 2006. The call can be accessed by dialing 800-289-0498 (domestic) or 1-913-981-5539 (international) five minutes prior to the start time. A live webcast of the conference call can be accessed on Infinity's website at http://www.ipi.com/. An archived version of the webcast will be available on Infinity's website for 30 days. About Infinity Pharmaceuticals, Inc. Infinity is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients first-in-class or best-in-class medicines for the treatment of cancer and related conditions. Additional Information about the DPI-Infinity Merger and Where to Find It In connection with the proposed merger between Discovery Partners International, Inc. (DPI) and Infinity, on August 7, 2006, DPI filed an amended registration statement on Form S-4 that contains a proxy statement/prospectus, which registration statement has been declared effective by the Securities and Exchange Commission (SEC). Investors and security holders of DPI and Infinity are urged to read the proxy statement/prospectus (including any amendments or supplements to the proxy statement/prospectus) regarding the proposed merger because it contains important information about DPI, Infinity, and the proposed merger. Security holders will be able to obtain a copy of the proxy statement/prospectus, as well as other filings containing information about DPI and Infinity, without charge, at the SEC's Internet site (http://www.sec.gov/). Copies of the proxy statement/prospectus can also be obtained, without charge, by directing a request to Discovery Partners International, Inc., 9640 Towne Centre Drive, San Diego, CA 92121, Attention: Investor Relations, Telephone: (858) 455-8600. Participants in the Solicitation DPI and its directors and executive officers and Infinity and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of DPI in connection with the proposed merger of DPI with Infinity. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of DPI is also included in DPI's proxy statement for its 2006 Annual Meeting of Stockholders, which was filed with the SEC on April 6, 2006. This document is available free of charge at the SEC's web site (http://www.sec.gov/) and from Investor Relations at DPI at the address described above. Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ materially from such forward-looking statements are more fully described in DPI's registration statement on Form S-4, as amended, as filed with the Securities and Exchange Commission and DPI's other SEC reports. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. Any forward-looking statements contained in this press release speak only as of the date hereof and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts: Investors: John Evans 617.453.1254 Media: Monique Allaire 617.453.1105 DATASOURCE: Infinity Pharmaceuticals, Inc. CONTACT: Investors: John Evans, +1-617-453-1254, , or Media: Monique Allaire, +1-617-453-1105, , both of Infinity Pharmaceuticals, Inc. Web site: http://www.ipi.com/

Copyright